{"id":9838,"date":"2012-06-08T11:29:23","date_gmt":"2012-06-08T15:29:23","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=9838"},"modified":"2012-06-08T11:33:57","modified_gmt":"2012-06-08T15:33:57","slug":"biomarker-diagnostics-company-gains-40m-in-venture-funding","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=9838","title":{"rendered":"Biomarker Diagnostics Company Gains $40M in Venture Funding"},"content":{"rendered":"

\"Loose<\/a>Astute Medical Inc.<\/a> in San Diego, a developer of biomarker-based medical diagnostics, says it completed $40.4 million in series C venture financing, the third cycle of funding after initial start-up. The funding round was led by MPM Capital and included new investor Kaiser Permanente Ventures, as well as existing investors De Novo Ventures, Delphi Ventures, Domain Associates, and Johnson & Johnson Development Corporation.<\/p>\n

Astute Medical identifies and validates protein biomarkers that can be used for diagnosing diseases, particularly with labratory (in vitro<\/em>) tests. The company’s current interests include tests involving abdominal pains, acute coronary syndromes, cerebrovascular injury (e.g., stroke), kidney injury, and sepsis.<\/p>\n

The company plans to use the proceeds from the round to begin commercializing its first product, as well as advance and expand its research, development, and validation of biomarker-based lab tests. Details about its first commercial product were not disclosed.<\/p>\n

Astute Medical was founded in 2007 by former executives in the diagnostics company Biosite Inc.\u00a0 The company completed its series A funding round in May 2008, with $6.2 million led by DeNovo Ventures. Its series B round, was divided into two segments: $26.5 million in May 2010, and $13 million in March 2011.<\/p>\n

Read more:<\/p>\n